PsiOxus Therapeutics Limited

40 articles about PsiOxus Therapeutics Limited

• PsiOxus Appoints Dr Paolo Paoletti As Chairman Of The Board

  1/7/2016

• PsiOxus Initiates Combination Study Of Merck & Co.’s Keytruda With Oncolytic Virus Enadenotucirev

  12/16/2015

• PsiOxus Scores $38.5 Million Series C

  5/19/2015

• PsiOxus Therapeutics Limited To Present Promising New Data On Novel Oncolytic Immunoncology Platform At American Association for Cancer Research 2015

  4/16/2015

• PsiOxus Therapeutics Limited Expands Clinical Studies For Immuno-Oncolytic Treatment Following Positive Response To Intravenous Delivery

  4/16/2015

• PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine

  1/13/2015

• PsiOxus Therapeutics Limited Select BioOutsource To Support Clinical Sample Analysis For OCTAVE Ovarian Cancer Study

  6/19/2014

• PsiOxus Therapeutics Limited Initiates "OCTAVE" Ovarian Cancer Study For Oncolytic Vaccine Enadenotucirev

  6/17/2014

• PsiOxus Therapeutics Limited Announces Positive Study Results Of Oncolytic Vaccine Enadenotucirev At 2014 American Society of Clinical Oncology Annual Meeting

  6/3/2014

• PsiOxus Therapeutics Limited To Release Study Results Of Oncolytic Vaccine Enadenotucirev In Cancer Patients

  5/13/2014

• PsiOxus Therapeutics Limited Cancer-Wasting Drug Better Than Placebo In Phase 2 Study

  11/13/2013

• BioIndustry Association Congratulates UK Company PsiOxus Therapeutics Limited on Being Named EuropaBio's Most Innovative European Biotech SME

  10/3/2013

• PsiOxus Therapeutics Limited Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102

  3/4/2013

• DTRA Awards $3.3 Million Contract to PsiOxus Therapeutics Limited to Develop Biodefence Vaccine Adjuvants

  1/16/2013

• UK Government Awards £1.7 Million Grant to PsiOxus Therapeutics Limited for Second Phase I/II Clinical Trial of Cancer Vaccine

  11/5/2012

• IXICO and PsiOxus Therapeutics Limited Win Significant Funding From Government-Backed Biomedical Catalyst

  11/5/2012

• PsiOxus Therapeutics Limited Launches Phase I/II Clinical Trial of Oncolytic Vaccine With Dosing of Patient With Metastatic Cancer

  9/26/2012

• Imperial Innovations Leads $34 Million Funding Round for PsiOxus Therapeutics Limited

  7/9/2012

• PsiOxus Therapeutics Limited Moves into New Facilities on Milton Park to Accommodate Expansion

  4/24/2012

• PsiOxus Therapeutics Limited Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102

  3/17/2011